December 2016
-
CDMO Experic and particle engineering specialist Flurry Powders have announced a partnership to offer development services for inhaled and nasal drug formulations that require specialized particle engineering and manufacturing. The companies cite potential opportunities for dry… Read more . . .
-
Interna Therapeutics has announced that under an agreement with the University of Oxford researchers led by Oxford’s Helen McShane will conduct a Phase 2a study of the company’s intranasal molecular nano-motor (MNM)-siRNA drug against SARS-CoV-2.… Read more . . .
-
Nexalis Therapeutics, which recently changed its name from InhaleRx, has announced the initiation of a Phase 1 trial of its IRX-616a cannabidiol MDI, which the company is developing for the treatment of panic disorder. In… Read more . . .
-
Zydus Lifesciences has announced the launch of a foldable MDI spacer after acquiring marketing and commercialization rights to the device from Mumbai-based AeroDel Technology Innovations. The spacer, which AeroDel calls A202, is being marketed by… Read more . . .
-
Inhaled drug developer Transpire Bio announced that it has hired Ewan Livesey as Head of Business Development. Livesey has more than 30 years experience in business and corporate development and has served in a number… Read more . . .
-
Nasus Pharma announced that topline data from its Phase 2 trial of NS002 intranasal dry powder epinephrine versus EpiPen intramuscular epinephrine “demonstrated multiple significant advantages for NS002 across key pharmacokinetic and pharmacodynamic parameters.” The company… Read more . . .
-
Australian biopharm Covirix Medical, which is developing a broad-spectrum antiviral, has signed a letter of intent with Aptar Pharma for a feasibility study evaluating delivery of the antiviral via Aptar’s Orbital dry powder inhaler. The… Read more . . .
-
Nuance Pharma announced that the Hong Kong Drug Office has approved Ohtuvayre ensifentrine inhalation suspension for the treatment of COPD. According to Nuance, Ohtuvarye had been available through certain medical facilities in Macau and Hong Kong… Read more . . .
-
Orbia Fluor & Energy Materials (previously Koura, Mexichem) has announced the submission of a drug master file for its HFA 152a MDI propellant, marketed as Zephex 152a. The company kicked off the transition to low global warming potential… Read more . . .
-
Chiesi and Inhalation CDMO Bespak have announced an expansion of an existing partnership to increase manufacturing capacity for LGWP propellant MDIs at Bespak’s Holmes Chapel, UK site. Chiesi announced plans to launch an HFA 152a inhaler by… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland